Ering Pharmaceuticals Semi-Annual Report Announces 50.35% YoY Increase in Operating Income

August 27, 2020, Ering Pharmaceuticals disclosed its 2020 half-yearly report. During the reporting period, the company achieved operating income of nearly RMB4,487 million, up 50.35% YoY; net profit attributable to shareholders of listed companies was RMB714 million, up 57.05% YoY, more than for the whole of last year; and research and development investment was RMB307 million, up 52.75% YoY, with continuous research and development investment helping to develop the high quality of Ling Pharmaceuticals.During the reporting period, the treatment of acute trachea, bronchitis, Lianhua Qing cough tablets obtained drug registration approval, is after Lianhua Qing plague in the field of cold respiratory system another heavy variety, is expected to become the company's new business growth point. In addition, under the guidance of the theory of the eight words of health care, the new Chinese medicine noobal puzzle antheist tablets have been declared new drugs.Up to now, Toling Pharmaceuticals has undertaken two national 973, national 863, national "12th Five-Year Plan" major new drug creation, national key research and development plans and other national, provincial and ministerial-level topics more than 30, research and development patents in more than 10 kinds of drugs, of which 7 are included in the national medical insurance directory, 5 are national-based drugs, and formed a series of patent drug clusters at different stages of research and development. The company has won a total of 586 patents, won 6 national science and technology awards, by Yiling Pharmaceutical Subsidiary Hebei Yiling Pharmaceutical Research Institute as the first main research unit completed by the "Chinese medicine vein thesis construction and guidance microvascular lesions prevention and control" project won the 2019 National Science and Technology Progress First Prize.It is reported that, combined with the national key research and development plan - the pulse theory camp health theory to guide the prevention and treatment of cardiovascular events chain research, ling pharmaceutical industry layout of 5 clinical evidence-based research, of which chinese traditional medicine to mortality hard end as the main indicator of evidence-based medical research "heart intervention coronary artery fragile plaque clinical research" and "tweed strong heart capsules on the evaluation of chronic heart failure complex endpoint events" is progressing smoothly.In the field of research and development of a class of innovative drugs, there are currently 4 types of innovative drugs into the clinical stage, more than 10 types of innovative drugs in the pre-clinical research stage, of which aniline lofen injection has completed phase II clinical, is preparing for phase III clinical. Yiling Pharmaceuticals said that the product will be on the market for the vast number of postoperative pain patients to provide non-steroidal analgesic anti-inflammatory drugs intravenous dosage form.In the research and development and production of patented Chinese medicine at the same time, Toling Pharmaceuticals to promote "zero-level prevention", and actively lay out the large health industry. Company subsidiary to Ling Health City developed and completed the series of brand hand wash, hand cream, antibacterial spray, oral spray, air purification gel and other products, with the help of Lianhua brand potential energy, and strive to become the first brand of respiratory protection.With the company's further growth in research and development investment and new products on the market, will open up the company's future growth space. Ering Pharmaceuticals said that the company's patented products with its excellent clinical efficacy has entered a number of clinical guidelines, expert consensus or diagnosis and treatment programs, for the academic promotion of products to create favorable conditions for the company's products to better serve the clinical foundation. Under the background of the vigorous promotion of the current national policy, the company has ushered in new opportunities for development, and in the future, The pharmaceutical industry will continue to maintain the advantages of research and development and production, in order to promote the modernization, industrialization and internationalization of Chinese medicine, and promote the revitalization and development of Chinese medicine. (
.
)